Factors Affecting Health-Care Costs and Hospitalizations among Diabetic Patients in Thai Public Hospitals. Chaikledkaew U1,2, Pongchareonsuk P1, Chaiyakunapruk N3,4,5, Ongphiphadhanakul B6. 1Department of Pharmacy, Faculty of Pharmacy, Mahidol University, Bangkok,Thailand; 2Health Interventio

Cost-Effectiveness Analysis of Thiazolidinediones in Uncontrolled Type 2 Diabetic Patients Receiving Sulfonylureas and Metformin in Thailand. Suphachai Chirakup1,2 Nathorn Chaiyakunapruk1,3,4 Usa Chaikledkeaw5,6 Petcharat Pongcharoensuk5 Boonsong Ongphiphadhanakul7 Stephane Roze8 William J. Valenti

Strengthening Cost-Effectiveness Analysis in Thailand through the Establishment of the Health Intervention and Technology Assessment Program. Tantivess S1 Teerawattananon Y1 Mills A1 1 Health Intervention and Technology Assessment Program, Ministry of Public Health, Nonthaburi, Thailand 2 London

In this issue, the main article will focused on how HTA units in the Asian-Pacific region communicate with their stakeholders in order to push forward their research result. Secondly, we recently greet our two new members, HealthPact (Australia) and Department of Health (the Philippines), therefo

COVID-19 has been inevitably staying with us for almost a year and a half since the first outbreak. It induces us to seek for more knowledge in order to survive and control this harsh situation, not only from healthcare perspective but also economic and political ones. HTA is a great helping hand fo

For full text, click here http://www.translational-medicine.com/content/pdf/1479-5876-11-1.pdf

Advanced health biotechnologies in Thailand: redefining policy directions. Román Pérez Velasco1*, Usa Chaikledkaew2,3, Chaw Yin Myint2 , Roongnapa Khampang2 , Sripen Tantivess2 and Yot Teerawattananon2* Abstract Background: Thailand faces a significant burden in terms of treating and managi

Cost-utility analysis of 10- and 13-valent pneumococcal conjugate vaccines: Protection at what price in the Thai context? Wantanee Kulpenga, b, , , , Pattara Leelahavaronga, , Waranya Rattanavipaponga, , Vorasith Sornsrivichaib, , Henry C. Baggettc, , Aronrag Meeyaia, d, , , Warunee Punpaniche, ,

A cost–utility analysis of alternative drug regimens for newly diagnosed severe lupus nephritis patients in Thailand. Adun Mohara1, Román Pérez Velasco1, Naiyana Praditsitthikorn1,2, Yingyos Avihingsanon3 and Yot Teerawattananon1 1Health Intervention and Technology Assessment Program (HITAP),

ROONGNAPA KHAMPANG1,2, SAWITRI ASSANANGKORNCHAI1 & YOT TEERAWATTANANON2 1Epidemiology Unit, Faculty of Medicine, Prince of Songkla University, HatYai, Songkhla, Thailand, and 2Health Intervention and Technology Assessment Program, Department of Health, Ministry of Public Health, Nonthaburi, Tha